Sugi Predict
/ Targets
/ CSF1R
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to CSF1R by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Study of Vimseltinib for Tenosynovial Giant Cell Tumor |
PHASE3 | ACTIVE_NOT_RECRUITING |
| Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT) |
PHASE3 | ACTIVE_NOT_RECRUITING |
| Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From Lower-risk Myelodysplastic Syndrome. |
PHASE3 | ACTIVE_NOT_RECRUITING |
| Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms |
PHASE1/PHASE2 | RECRUITING |
| Phase Ib/II Study of Primary Chemotherapy With Paclitaxel, Gemcitabine, and Sunitinib |
PHASE1/PHASE2 | COMPLETED |
| Study of [11C]CPPC as a Clinical PET Radioligand Biomarker of Microglial Activation in ALS |
PHASE1/PHASE2 | NOT_YET_RECRUITING |
| Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) |
PHASE1/PHASE2 | RECRUITING |
| Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor |
PHASE1/PHASE2 | COMPLETED |
| Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma |
PHASE2 | COMPLETED |
| LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma |
PHASE1/PHASE2 | COMPLETED |
| The Effectiveness of GM-CSF in HIV-Positive Patients Who Are Also Receiving Anti-HIV Therapy |
PHASE2 | COMPLETED |
| Safety and Efficacy of Tag-7 Gene-modified Vaccine in Locally Advanced or Metastatic Malignant Melanoma or Kidney Cancer |
PHASE1/PHASE2 | COMPLETED |
| Efficacy and Safety of Namilumab (MT203) for Plaque Psoriasis |
PHASE2 | COMPLETED |
| Safety and Efficacy of PMT Therapy of hPAP |
PHASE1/PHASE2 | RECRUITING |
| Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer |
PHASE2 | RECRUITING |
| Intranasal Inhalations of Bioactive Factors Produced by M2 Macrophages in Patients With Organic Brain Syndrome |
PHASE1/PHASE2 | COMPLETED |
| Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia |
PHASE1/PHASE2 | COMPLETED |
| GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin Lymphoma |
PHASE2 | COMPLETED |
| Sunitinib for Advanced Thymus Cancer Following Earlier Treatment |
PHASE2 | COMPLETED |
| Reirradiation and Niraparib in Patients With Recurrent Glioblastoma |
PHASE1 | WITHDRAWN |
| Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors |
PHASE1 | ACTIVE_NOT_RECRUITING |
| Interleukin-34 Level in Periodontal Disease |
nan | UNKNOWN |
| A Clinical Study of Sorafenib Combined With Gefitinib for the Treatment of pNET |
nan | RECRUITING |
| IL-34 Levels in Various Types of Periodontitis |
nan | COMPLETED |
| Assessment of Salivary GM-CSF, MIP, and IL-1β Levels in Subjects With Varying Periodontal Conditions |
nan | RECRUITING |
| Clinical Trial Protocol for the Combined Use of VAG in the Treatment of ND-AML |
nan | RECRUITING |
| Intrauterine Infusion of GCSF and Reproductive Outcomes in Infertile Women with History of RIF |
nan | COMPLETED |
| Interleukin-34 in Stage I and II Periodontitis |
nan | COMPLETED |
| A Multicenter Study of Avapritinib Efficacy and Safety of Metastatic or Unresectable Gastrointestinal Stromal Tumors |
nan | RECRUITING |
| Activity of Pre-Osteoclasts and Osteoclasts Over Time in Postmenopausal Women Treated With Denosumab or Zoledronic Acid |
nan | WITHDRAWN |
Related proteins — ESM-2 sequence neighbours (a CSF1R binder may also engage these)